|
시장보고서
상품코드
1494303
북미의 감염증 진단 시장 전망(-2030년) : 지역별 분석 - 제품, 기술, 용도, 검사 유형, 최종 사용자별 분석North America Infectious Disease Diagnostics Market Forecast to 2030 - Regional Analysis - By Product, Technology, Application Type, Testing Type, and End User |
||||||
북미의 감염증 진단 시장 규모는 2022년 186억 8,443만 달러로 평가되었고, 2022-2030년간 연평균 5.5% 성장하여 2030년에는 287억 1,807만 달러에 달할 것으로 예측됩니다.
감염증 진단 연구개발에 대한 집중과 자금 조달 증가가 북미 감염 진단 시장을 주도하고 있습니다.
연구개발(R&D)은 제약 및 바이오제약 기업의 비즈니스에 필수적인 요소입니다. R&D를 통해 시장 진출기업들은 의학적으로나 상업적으로 큰 잠재력을 가진 다양한 치료용 신제품을 개발할 수 있습니다. 또한, 신흥국 시장의 주요 기업들은 첨단 기술을 개발하고 더 많은 수익을 창출하기 위해 R&D에 투자하고 있습니다. 감염 환자 수 증가, 실험실용량 부족, 분자 검사 시약 부족에 대응하기 위해 일부 진단 테스트 제조업체는 실험실 밖에서 쉽게 검사할 수 있는 신속하고 사용하기 쉬운 장비를 제공합니다. 간이 검사 키트는 검체에서 병원체 단백질을 검출하거나 혈액이나 혈청에서 감염에 반응하여 생성된 인간 항체를 검출합니다.
아래는 제조업체가 수행 한 몇 가지 주요 자금 조달 이니셔티브 목록입니다.
- 지난 3월, 세계 에이즈, 말라리아, 결핵 퇴치 기금은 캐나다가 세계기금의 코로나19 대응 메커니즘(C19RM)에 6,000만 캐나다 달러(4,399만 달러)를 기부하기로 결정했다고 발표했습니다. 이 기금은 중저소득 국가에 생명을 구할 수 있는 진단 검사, 치료 및 개인보호장비(PPE)를 제공하는 데 사용될 예정입니다.
- 2021년 9월, 바이든-해리스 행정부는 미국 공중보건 및 의료 부문 전반의 감염 통제 및 예방 활동을 강화하기 위해 21억 달러를 투자했습니다. 바이든-해리스 행정부는 CDC를 통해 미국 구호 프로그램에 자금을 투자하여 미국의 주, 지방 및 지역 보건국 및 기타 파트너 조직에 미국의 전염병에 대응했습니다.
이러한 감염증 진단 분야의 연구개발 및 자금 조달에 대한 관심이 높아짐에 따라 북미의 감염증 진단 시장 성장에 유리한 기회를 창출할 수 있을 것으로 기대됩니다.
북미 감염성 질환 진단 시장 개요
미국 내 감염성 질환 진단 시장의 성장은 주로 감염성 질환 증가, 노인 인구 증가, 주요 기업의 제품 출시 증가에 기인합니다. 일반적으로 60세 이상 노인은 면역력이 떨어지기 때문에 고령화는 전염병의 두드러진 위험 요인입니다. 2020년 인구문제연구소가 발표한 조사에 따르면 미국의 65세 이상 인구는 2020년에는 5,500만 명, 2060년에는 9,500만 명에 달할 것으로 예상됩니다. 미국 규제 당국은 다양한 적응증에 대한 진단 및 치료를 위한 현장 진료(POC) 제품 개발에 유리한 정책을 시행하고 있습니다. 예를 들어, 2021년 3월 미국 식품의약국(FDA)은 Binx Health IO CT/NG Assay를 지역 밀착형 클리닉, 응급 의료 환경 및 외래 의료 시설용으로 승인했습니다. 2022년 5월, 세계 최고의 의료 기술 기업인 벡톤 디킨슨 앤 컴퍼니(BD)는 미국 시장에 새로운 감염성 질환을 위한 전자동 고처리량 분자진단 플랫폼을 출시할 예정이라고 발표했습니다. 새로운 BD COR MX 장비는 BD COR 플랫폼의 분석기 옵션으로 FDA 510(k) 승인을 받아 출시되었으며, BD CTGCTV2 분자 분석은 새로운 시스템에서 사용할 수 있는 첫 번째 검사로, 가장 널리 퍼진 세 가지 비바이러스성 감염(STI), 임질(GC), 클라미디아 트라코마티스(CT), 트리코모나스 질염(TV)을 검출하는 단일 검사입니다.
북미의 감염증 진단 시장 매출 및 2030년까지의 예측(금액)
북미 감염성 질환 진단 시장 세분화
북미의 감염증 진단 시장은 제품, 기술, 응용 분야, 검사 유형, 최종 사용자, 국가별로 세분화되어 있습니다.
제품별로 북미의 감염증 진단 시장은 키트 및 시약, 기기, 소프트웨어 및 서비스로 구분되며, 2022년에는 키트 및 시약 부문이 가장 큰 점유율을 차지할 것으로 예상됩니다.
기술별로 북미의 감염증 진단 시장은 바이오센서, 면역진단, 분자기반 진단기술, 임상생물학, 기타로 구분되며, 2022년에는 면역진단법이 가장 큰 점유율을 차지할 것으로 예상됩니다. 면역 진단법 부문은 효소 결합 면역 흡착 분석법(ELISA), 웨스턴 블롯 분석법, 면역 형광 분석법으로 세분화됩니다. 분자 기반 진단 기술 부문은 중합 효소 연쇄반응(PCR), in-situ 하이브리드 화, 등온 핵산 증폭 기술(INAAT), 차세대 시퀀싱(NGS), DNA 마이크로어레이 및 기타로 세분화됩니다.
용도별로는 북미의 감염증 진단 시장은 실험실 검사와 현장 검사로 나뉘며, 2022년에는 실험실 검사 부문이 가장 큰 비중을 차지할 것으로 예상됩니다.
검사 유형에 따라 북미 감염성 질환 진단 시장은 크게 인체용 검사와 동물용 검사로 나뉘며, 2022년에는 인체용 검사 부문이 큰 비중을 차지할 것으로 예상됩니다. 인간 검사 부문은 HIV, 간염, HAI, HPV, 결핵, 독감, 기타로 세분화됩니다.
최종 사용자별로 북미의 감염증 진단 시장은 진단 실험실, 병원 및 클리닉, 연구기관, 재택의료, 기타로 구분되며, 2022년에는 진단 실험실 부문이 가장 큰 점유율을 차지할 것으로 예상됩니다.
국가별로는 북미의 감염증 진단 시장은 미국, 캐나다, 멕시코로 구분되며, 2022년 북미의 감염증 진단 시장은 미국이 주도하고 있습니다.
Abbott Laboratories, Bruker Corp, Cardinal Health Inc, F. Hoffmann-La Roche Ltd, Trinity Biotech Plc, Danaher Corp, Bio-Rad Laboratories Inc, ACON Laboratories Inc, DiaSorin SpA 등이 북미의 감염증 진단 시장에서 사업을 전개하는 주요 기업들입니다.
목차
제1장 서론
제2장 주요 요약
- 주요 인사이트
- 북미의 감염증 진단 시장 : 국가별
제3장 조사 방법
- 조사 범위
- 2차 조사
- 1차 조사
제4장 북미의 감염증 진단 시장 - 주요 산업 역학
- 시장 성장 촉진요인
- 시장 성장 억제요인
- 시장 기회
- 향후 동향
- 영향 분석
제5장 감염증 진단 시장 : 북미 시장 분석
- 북미의 감염증 진단 시장 매출(2022년-2030년)
제6장 북미의 감염증 진단 시장 - 2030년까지 매출과 예측 : 제품별
- 북미의 감염증 진단 시장 매출 점유율 : 제품별(2022년·2030년)
- 키트 및 시약
- 기기
- 소프트웨어 및 서비스
제7장 북미의 감염증 진단 시장 - 2030년까지 매출과 예측 : 기술별
- 북미의 감염증 진단 시장 매출 점유율 : 기술별(2022년·2030년)
- 바이오센서 기반
- 면역진단 기술
- 분자 기반 진단 기술
- 임상 생물학
- 기타
제8장 북미의 감염증 진단 시장 - 2030년까지 매출과 예측 : 용도 유형별
- 북미의 감염증 진단 시장 매출 점유율 : 용도 유형별(2022년·2030년)
- POC(Point of Care) 검사
- 실험실 검사
제9장 북미의 감염증 진단 시장 - 2030년까지 매출과 예측 : 검사 유형별
- 북미의 감염증 진단 시장 매출 점유율 : 검사 유형별(2022년·2030년)
- 인간용 검사
- 동물용 검사
제10장 북미의 감염증 진단 시장 - 2030년까지 매출과 예측 : 최종사용자별
- 북미의 감염증 진단 시장 매출 점유율 : 최종사용자별(2022년·2030년)
- 진단 실험실
- 병원 및 진료소
- 연구기관
- 홈케어 환경
- 기타
제11장 북미의 감염증 진단 시장 : 국가별 분석
- 미국
- 캐나다
- 멕시코
제12장 업계 상황
- 시장 진출기업 성장 전략(%)
- 유기적 발전
- 무기적 발전
제13장 기업 개요
- Abbott Laboratories
- Bruker Corp
- Cardinal Health Inc
- F. Hoffmann-La Roche Ltd
- Trinity Biotech Plc
- Danaher Corp
- Bio-Rad Laboratories Inc
- ACON Laboratories Inc
- DiaSorin SpA
제14장 부록
LSH 24.06.21The North America infectious disease diagnostics market was valued at US$ 18,684.43 million in 2022 and is expected to reach US$ 28,718.07 million by 2030; it is estimated to grow at a CAGR of 5.5% from 2022 to 2030.
Increasing Focus on R&D and Funding in Infectious Disease Diagnostics Drive North America Infectious Disease Diagnostics Market
Research and development (R&D) is an essential component of the business of pharmaceutical and biopharmaceutical companies. R&D enables market players to come up with new products for various therapeutic applications with significant medical and commercial potential. Moreover, leading market players invest in R&D to develop advanced technologies and generate more revenue. In response to the growing cases of infectious diseases and the shortage of laboratory capabilities and molecular testing reagents, some diagnostic testing manufacturers offer fast and easy-to-use devices to facilitate out-of-laboratory testing. The simple test kits detect proteins of pathogens from samples or human antibodies that are produced in response to infection in blood or serum.
Following is a list of a few key funding initiatives undertaken by the manufacturers:
- In March 2022, the Global Fund to Fight AIDS, Malaria, and Tuberculosis acclaimed the decision by Canada to contribute CAD 60 million (US$ 43.99 million) to the Global Fund's COVID-19 Response Mechanism (C19RM). The funding will help provide life-saving diagnostic tests, treatments, and personal protective equipment (PPE) to low- and middle-income countries.
- In September 2021, the Biden-Harris Administration invested US$ 2.1 billion to enhance infection control and prevention activities across the US public health and healthcare sectors. The Biden-Harris administration, operating through the CDC, invested funds in the US rescue programs to address state, local, and territorial health departments and other partner organizations about infectious diseases in the US.
Thus, rising focus on R&D and funding in infectious disease diagnostics is expected to create lucrative opportunities for the growth of the North America infectious disease diagnostics market.
North America Infectious Disease Diagnostics Market Overview
The infectious diseases diagnostics market growth in the US is primarily driven by the increasing prevalence of infectious diseases, rising geriatric population, and growing number of product launches by key players. Aging is a prominent risk factor for infectious diseases as people above 60 generally have compromised immunity. According to a study published by the Population Reference Bureau in 2020, the population of individuals aged 65 and above was 55 million in the US in 2020, and the number is expected to reach 95 million by 2060. Regulatory agencies in the US are imposing favorable policies for the development of point-of-care (POC) products for the diagnosis and treatment of various indications. For instance, in March 2021, the US Food Drug Administration (FDA) authorized Binx Health IO CT/NG Assay for community-based clinics, urgent care settings, and outpatient healthcare facilities; it is the first POC testing product for diagnosing chlamydial and gonorrheal infections. In May 2022, Becton Dickinson and Company (BD), one of the leading global medical technology companies, announced the launch of its new, fully automated, high-throughput molecular diagnostics platform for infectious diseases for the market in the US. The new BD COR MX instrument was launched as an analytical instrument option for the BD COR platform, with 510(k) clearance from the FDA. The BD CTGCTV2 molecular assay, the first test available on the new system, is a single test that detects the three most prevalent non-viral sexually transmitted infections (STIs)-Neisseria gonorrhoeae (GC), Chlamydia trachomatis (CT), and Trichomonas vaginalis (TV).
North America Infectious Disease Diagnostics Market Revenue and Forecast to 2030 (US$ Million)
North America Infectious Disease Diagnostics Market Segmentation
The North America infectious disease diagnostics market is segmented based on product, technology, application type, testing type, end user, and country.
Based on product, the North America infectious disease diagnostics market is segmented into kits & reagents, instruments, and software & services. The kits & reagents segment held the largest share in 2022.
By technology, the North America infectious disease diagnostics market is segmented into biosensor-based, immunodiagnostics, molecular-based diagnostic techniques, clinical biology, and others. The immunodiagnostics segment held the largest share in 2022. The immunodiagnostics segment is further subsegmented into enzyme-linked immunosorbent assay (ELISA), western blotting analysis, and immunofluorescence assay. The molecular-based diagnostic techniques segment is further subsegmented into polymerase chain reaction (PCR), in situ hybridization, isothermal nucleic acid amplification technology (INAAT), next-generation sequencing (NGS), DNA microarrays, and others.
By application type, the North America infectious disease diagnostics market is bifurcated into laboratory testing and point-of-care testing. The laboratory testing segment held a larger share in 2022.
By testing type, the North America infectious disease diagnostics market is bifurcated into human testing and veterinary testing. The human testing segment held a larger share in 2022. The human testing segment is further subsegmented into HIV, hepatitis, HAIs, HPV, tuberculosis, influenza, and others.
By end user, the North America infectious disease diagnostics market is segmented into diagnostic laboratories, hospitals & clinics, research institutes, homecare settings, and others. The diagnostic laboratories segment held the largest share in 2022.
Based on country, the North America infectious disease diagnostics market is segmented into the US, Canada, and Mexico. The US dominated the North America infectious disease diagnostics market in 2022.
Abbott Laboratories, Bruker Corp, Cardinal Health Inc, F. Hoffmann-La Roche Ltd, Trinity Biotech Plc, Danaher Corp, Bio-Rad Laboratories Inc, ACON Laboratories Inc, and DiaSorin SpA are some of the leading companies operating in the North America infectious disease diagnostics market.
Table Of Contents
1. Introduction
- 1.1 The Insight Partners Research Report Guidance
- 1.2 Market Segmentation
2. Executive Summary
- 2.1 Key Insights
- 2.2 North America Infectious Disease Diagnostics Market, by Country (US$ Million)
3. Research Methodology
- 3.1 Coverage
- 3.2 Secondary Research
- 3.3 Primary Research
4. North America Infectious Disease Diagnostics Market - Key Industry Dynamics
- 4.1 Market Drivers:
- 4.1.1 Rising Incidence of Infectious Diseases
- 4.1.2 Rising Application of Diagnostics in Veterinary Infectious Disease
- 4.2 Market Restraints
- 4.2.1 Inadequate Reimbursement Scenario
- 4.3 Market Opportunities
- 4.3.1 Increasing Focus on R&D and Funding in Infectious Disease Diagnostics
- 4.4 Future Trends
- 4.4.1 Rising Number of Product Approvals and Launches
- 4.5 Impact Analysis:
5. Infectious Disease Diagnostics Market - North America Market Analysis
- 5.1 North America Infectious Disease Diagnostics Market Revenue (US$ Mn), 2022 - 2030
6. North America Infectious Disease Diagnostics Market - Revenue and Forecast to 2030 - by Product
- 6.1 Overview
- 6.2 North America Infectious Disease Diagnostics Market Revenue Share, by Product, 2022 & 2030 (%)
- 6.3 Kits & Reagents
- 6.3.1 Overview
- 6.3.2 Kits & Reagents: North America Infectious Disease Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
- 6.4 Instruments
- 6.4.1 Overview
- 6.4.2 Instruments: North America Infectious Disease Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
- 6.5 Software & Services
- 6.5.1 Overview
- 6.5.2 Software & Services: North America Infectious Disease Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
7. North America Infectious Disease Diagnostics Market - Revenue and Forecast to 2030 - by Technology
- 7.1 Overview
- 7.2 North America Infectious Disease Diagnostics Market Revenue Share, by Technology, 2022 & 2030 (%)
- 7.3 Biosensor-based
- 7.3.1 Overview
- 7.3.2 Biosensor-based: North America Infectious Disease Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
- 7.4 Immunodiagnostics
- 7.4.1 Overview
- 7.4.2 Immunodiagnostics: North America Infectious Disease Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
- 7.4.2.1 North America Infectious Disease Diagnostics Market, for Immunodiagnostics by Technology, 2020-2030 (US$ Million)
- 7.5 Molecular-Based Diagnostic Techniques
- 7.5.1 Overview
- 7.5.2 Molecular-Based Diagnostic Techniques: North America Infectious Disease Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
- 7.5.2.1 North America Infectious Disease Diagnostics Market, for Molecular-Based Diagnostic Techniques by Technology, 2020-2030 (US$ Million)
- 7.6 Clinical Biology
- 7.6.1 Overview
- 7.6.2 Clinical Biology: North America Infectious Disease Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
- 7.7 Others
- 7.7.1 Overview
- 7.7.2 Others: North America Infectious Disease Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
8. North America Infectious Disease Diagnostics Market - Revenue and Forecast to 2030 - by Application Type
- 8.1 Overview
- 8.2 North America Infectious Disease Diagnostics Market Revenue Share, by Application Type, 2022 & 2030 (%)
- 8.3 Point-of-Care Testing
- 8.3.1 Overview
- 8.3.2 Point-of-Care Testing: North America Infectious Disease Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
- 8.4 Laboratory Testing
- 8.4.1 Overview
- 8.4.2 Laboratory Testing: North America Infectious Disease Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
9. North America Infectious Disease Diagnostics Market - Revenue and Forecast to 2030 - by Testing Type
- 9.1 Overview
- 9.2 North America Infectious Disease Diagnostics Market Revenue Share, by Testing Type, 2022 & 2030 (%)
- 9.3 Human Testing
- 9.3.1 Overview
- 9.3.2 Human Testing: North America Infectious Disease Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
- 9.3.2.1 North America Infectious Disease Diagnostics Market, for Human Testing by Testing Type, 2020-2030 (US$ Million)
- 9.4 Veterinary Testing
- 9.4.1 Overview
- 9.4.2 Veterinary Testing: North America Infectious Disease Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
10. North America Infectious Disease Diagnostics Market - Revenue and Forecast to 2030 - by End User
- 10.1 Overview
- 10.2 North America Infectious Disease Diagnostics Market Revenue Share, by End User, 2022 & 2030 (%)
- 10.3 Diagnostic Laboratories
- 10.3.1 Overview
- 10.3.2 Diagnostic Laboratories: North America Infectious Disease Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
- 10.4 Hospitals and Clinics
- 10.4.1 Overview
- 10.4.2 Hospitals and Clinics: North America Infectious Disease Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
- 10.5 Research Institutes
- 10.5.1 Overview
- 10.5.2 Research Institutes: North America Infectious Disease Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
- 10.6 Homecare Settings
- 10.6.1 Overview
- 10.6.2 Homecare Settings: North America Infectious Disease Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
- 10.7 Others
- 10.7.1 Overview
- 10.7.2 Others: North America Infectious Disease Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
11. North America Infectious Disease Diagnostics Market - Country Analysis
- 11.1 North America Infectious Disease Diagnostics Market - Country Analysis
- 11.1.1 North America Infectious Disease Diagnostics Market, by Country
- 11.1.1.1 US
- 11.1.1.1.1 Overview
- 11.1.1.1.2 US: North America Infectious Disease Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
- 11.1.1.1.3 US: North America Infectious Disease Diagnostics Market, by Product, 2020-2030 (US$ Million)
- 11.1.1.1.4 US: North America Infectious Disease Diagnostics Market, by Technology, 2020-2030 (US$ Million)
- 11.1.1.1.4.1 US: North America Infectious Disease Diagnostics Market, for Immunodiagnostics by Technology, 2020-2030 (US$ Million)
- 11.1.1.1.4.2 US: North America Infectious Disease Diagnostics Market, for Molecular-Based Diagnostic Techniques by Technology, 2020-2030 (US$ Million)
- 11.1.1.1.5 US: North America Infectious Disease Diagnostics Market, by Application Type, 2020-2030 (US$ Million)
- 11.1.1.1.6 US: North America Infectious Disease Diagnostics Market, by Testing Type, 2020-2030 (US$ Million)
- 11.1.1.1.6.1 US: North America Infectious Disease Diagnostics Market, for Human Testing by Testing Type, 2020-2030 (US$ Million)
- 11.1.1.1.7 US: North America Infectious Disease Diagnostics Market, by End User, 2020-2030 (US$ Million)
- 11.1.1.2 Canada
- 11.1.1.2.1 Overview
- 11.1.1.2.2 Canada: North America Infectious Disease Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
- 11.1.1.2.3 Canada: North America Infectious Disease Diagnostics Market, by Product, 2020-2030 (US$ Million)
- 11.1.1.2.4 Canada: North America Infectious Disease Diagnostics Market, by Technology, 2020-2030 (US$ Million)
- 11.1.1.2.4.1 Canada: North America Infectious Disease Diagnostics Market, for Immunodiagnostics by Technology, 2020-2030 (US$ Million)
- 11.1.1.2.4.2 Canada: North America Infectious Disease Diagnostics Market, for Molecular-Based Diagnostic Techniques by Technology, 2020-2030 (US$ Million)
- 11.1.1.2.5 Canada: North America Infectious Disease Diagnostics Market, by Application Type, 2020-2030 (US$ Million)
- 11.1.1.2.6 Canada: North America Infectious Disease Diagnostics Market, by Testing Type, 2020-2030 (US$ Million)
- 11.1.1.2.6.1 Canada: North America Infectious Disease Diagnostics Market, for Human Testing by Testing Type, 2020-2030 (US$ Million)
- 11.1.1.2.7 Canada: North America Infectious Disease Diagnostics Market, by End User, 2020-2030 (US$ Million)
- 11.1.1.3 Mexico
- 11.1.1.3.1 Overview
- 11.1.1.3.2 Mexico: North America Infectious Disease Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
- 11.1.1.3.3 Mexico: North America Infectious Disease Diagnostics Market, by Product, 2020-2030 (US$ Million)
- 11.1.1.3.4 Mexico: North America Infectious Disease Diagnostics Market, by Technology, 2020-2030 (US$ Million)
- 11.1.1.3.4.1 Mexico: North America Infectious Disease Diagnostics Market, for Immunodiagnostics by Technology, 2020-2030 (US$ Million)
- 11.1.1.3.4.2 Mexico: North America Infectious Disease Diagnostics Market, for Molecular-Based Diagnostic Techniques by Technology, 2020-2030 (US$ Million)
- 11.1.1.3.5 Mexico: North America Infectious Disease Diagnostics Market, by Application Type, 2020-2030 (US$ Million)
- 11.1.1.3.6 Mexico: North America Infectious Disease Diagnostics Market, by Testing Type, 2020-2030 (US$ Million)
- 11.1.1.3.6.1 Mexico: North America Infectious Disease Diagnostics Market, for Human Testing by Testing Type, 2020-2030 (US$ Million)
- 11.1.1.3.7 Mexico: North America Infectious Disease Diagnostics Market, by End User, 2020-2030 (US$ Million)
- 11.1.1.1 US
- 11.1.1 North America Infectious Disease Diagnostics Market, by Country
12. Industry Landscape
- 12.1 Overview
- 12.2 Growth Strategies Done by the Companies in the Market, (%)
- 12.3 Organic Developments
- 12.3.1 Overview
- 12.4 Inorganic Developments
- 12.4.1 Overview
13. Company Profiles
- 13.1 Abbott Laboratories
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
- 13.2 Bruker Corp
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
- 13.3 Cardinal Health Inc
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
- 13.4 F. Hoffmann-La Roche Ltd
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
- 13.5 Trinity Biotech Plc
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
- 13.6 Danaher Corp
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
- 13.7 Bio-Rad Laboratories Inc
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
- 13.8 ACON Laboratories Inc
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
- 13.9 DiaSorin SpA
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
14. Appendix
- 14.1 About Us
- 14.2 Glossary of Terms
